COMPANY
Meridian Bioscience
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Field Application Specialist, Chicago | US-IL-Chicago | Not stated | Oct 22, 2026 |
| Account Executive, St. Louis | US-MO-St. Louis | US-MO-Kansas City | Not stated | Oct 21, 2026 |
| Laboratory Assistant (m/f/x) | UK-London | Not stated | Oct 21, 2026 |
| Manager, Global Customer Operations | US-TN-Memphis | Not stated | Oct 16, 2026 |
| Senior Project Manager | US-Remote | Not stated | Oct 16, 2026 |
Timeline
- Trial start —: Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol source ↗
- Trial start Not phased (device or behavioral study): Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples. source ↗
- Trial start —: Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials source ↗
- Trial start Not phased (device or behavioral study): Validation of the GenePOC Strep A, C/G Assay for Detecting Group A, C and G β-hemolytic Streptococcus From Throat Swabs. source ↗
- Trial start —: Detection of Cytomegalovirus Virus in Neonates source ↗
- Trial start —: Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17 source ↗
- Trial start Phase 3: Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics source ↗
- Trial start Not phased (device or behavioral study): Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains source ↗
- Trial start —: Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14 source ↗
- Trial start Not phased (device or behavioral study): Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains source ↗
- Trial start Phase 3: Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection source ↗
- Trial start —: Detection of Mycoplasma Pneumoniae source ↗
- Trial start Phase 2: Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis source ↗
- Trial start Phase 2: BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH source ↗
- Trial start Not phased (device or behavioral study): Assessing Portal Hypertension With Methacetin Breath Test source ↗
- Trial start Not phased (device or behavioral study): Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function source ↗
- Trial start —: Detection of Chlamydia (CT) and Gonorrhea (NG) source ↗
- Trial start —: Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation source ↗
- Trial start Phase 3: Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori source ↗
- Trial start Phase 1: MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy source ↗
- Trial start Not phased (device or behavioral study): Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection source ↗
- Trial start Phase 2: Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI source ↗
- Trial start Phase 2: BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency source ↗
- Trial start Phase 4: 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors) source ↗
- Trial start —: Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics source ↗
Clinical trials (lead sponsor) 27
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT05681156 | Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol | Not listed | Completed | Feb 1, 2023 | Mar 23, 2023 (actual) |
| NCT00736840 | BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis | Phase 3 | Completed | 2008-08 | 2009-09 (actual) |
| NCT01433016 | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI | Phase 2 | Terminated | 2011-11 | 2012-05 (actual) |
| NCT01650831 | Show Equivalence of the Modified BreathID Compared to Currently Approved BreathID in H.Pylori Detection | Not phased (device or behavioral study) | Completed | 2012-10 | 2012-11 (actual) |
| NCT02143778 | Assessing Portal Hypertension With Methacetin Breath Test | Not phased (device or behavioral study) | Completed | 2014-11 | 2018-12 (actual) |
| NCT00375011 | Breath Test to Assess Hepatic Metabolic Reserve and to Predict Hepatic Decompensation in Cirrhotics | Not listed | Terminated | 2008-09 | Not listed |
| NCT02794805 | Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis | Phase 2 | Completed | 2015-06 | 2017-03 (actual) |
| NCT03439189 | Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14 | Not listed | Completed | Aug 28, 2016 | Apr 8, 2019 (actual) |
| NCT02010112 | Bag Mode BreathID Hp Validation Versus Endoscopy in Detection of Helicobacter Pylori | Phase 3 | Completed | 2014-01 | 2015-02 (actual) |
| NCT02084160 | Prediction Value of the BreathID 13C-Methacetin Breath Test for Hepatic Decompensation | Not listed | Completed | 2014-03 | 2018-10 (actual) |
| NCT00350714 | BreathID Multi-center HCV Liver Breath Test Study | Phase 2 | Terminated | 2006-07 | 2007-02 (actual) |
| NCT02905825 | Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics | Phase 3 | Completed | May 18, 2017 | Oct 30, 2017 (actual) |
| NCT03462576 | Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17 | Not listed | Terminated | Jun 28, 2017 | Jul 15, 2019 (actual) |
| NCT03611101 | Companion Protocol for ¹³C-Methacetin Breath Tests in BMS: NCT03486899, NCT03486912 Referenced Trials | Not listed | Completed | May 4, 2018 | Aug 18, 2020 (actual) |
| NCT01851252 | MBT Versus HVPG in Identifying Responders to Portal Hypertension Therapy | Phase 1 | Completed | 2013-10 | 2017-08 (actual) |
| NCT01259544 | BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency | Phase 2 | Completed | 2009-01 | 2009-02 (actual) |
| NCT02314026 | BREATHID Octanoate Breath Test With or Without Methacetin Breath Test for Correlation With Biopsy in NASH | Phase 2 | Completed | 2015-03 | 2017-06 (actual) |
| NCT02528721 | Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection | Phase 3 | Completed | 2015-10 | 2016-06 (actual) |
| NCT00825630 | 13-C Urea Breath Test Using BreathID System and PPIs (Proton Pump Inhibitors) | Phase 4 | Completed | 2008-11 | 2009-11 (actual) |
| NCT02187601 | Equivalence of New Breath AnalyzerCompared to Currently BreathID System in Assessment of Liver Function | Not phased (device or behavioral study) | Completed | 2014-08 | 2017-03 (actual) |
| NCT03422341 | Validation of the GenePOC Strep A, C/G Assay for Detecting Group A, C and G β-hemolytic Streptococcus From Throat Swabs. | Not phased (device or behavioral study) | Completed | Feb 14, 2018 | Jul 11, 2018 (actual) |
| NCT02968758 | Validation of the GenePOC CDiff Assay for the Detection of the Toxin B Gene From Toxigenic Clostridium Difficile Strains | Not phased (device or behavioral study) | Completed | Feb 6, 2017 | Aug 2, 2017 (actual) |
| NCT02718157 | Validation of the GenePOC GBS Assay for the Detection of the Cfb Gene From Streptococcus Agalactiae Strains | Not phased (device or behavioral study) | Completed | Aug 10, 2016 | Feb 7, 2017 (actual) |
| NCT03680898 | Clinical Validation of the Molecular-Based GenePOC Carba Assay for the Detection and Differentiation of Carbapenemase Genes in Rectal Swab Samples. | Not phased (device or behavioral study) | Unknown status (ClinicalTrials.gov) | Feb 12, 2019 | May 31, 2023 (estimated) |
| NCT03251261 | Detection of Cytomegalovirus Virus in Neonates | Not listed | Completed | Aug 2, 2017 | Mar 5, 2018 (actual) |
| NCT02055742 | Detection of Chlamydia (CT) and Gonorrhea (NG) | Not listed | Completed | Mar 1, 2014 | Sep 9, 2014 (actual) |
| NCT02511262 | Detection of Mycoplasma Pneumoniae | Not listed | Completed | 2015-08 | 2016-01 (actual) |
NIH awards 4
- NIH award 1R43AI060271-01 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI MORROW, KENNETH J; recipient as written: MERIDIAN BIOSCIENCE, INC., CINCINNATI, OH. Recombinant Immuno-Fragments for C. source ↗
- NIH award 5R44AI024832-03 FY1991: $265,254 awarded for that fiscal year; activity R44 (SBIR); PI NICKOL, ALLEN D; recipient as written: MERIDIAN BIOSCIENCE, INC., CINCINNATI, OH. DIAGNOSTICS FOR MYCOPLASMA HOMINIS AN source ↗
- NIH award 2R44AI024832-02A1 FY1990: $201,407 awarded for that fiscal year; activity R44 (SBIR); PI NICKOL, ALLEN D; recipient as written: MERIDIAN BIOSCIENCE, INC., CINCINNATI, OH. DIAGNOSTICS FOR MYCOPLASMA HOMINIS source ↗
- NIH award 1R43AI024832-01A1 FY1988: $50,000 awarded for that fiscal year; activity R43 (SBIR); PI NICKOL, ALLEN D; recipient as written: MERIDIAN BIOSCIENCE, INC., CINCINNATI, OH. ANTIGENS RELEVANT TO DIAGNOSIS OF MY source ↗
Open jobs 23
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Field Application Specialist, Chicago | US-IL-Chicago | Not stated | Oct 22, 2026 | Not stated |
| Account Executive, St. Louis | US-MO-St. Louis | US-MO-Kansas City | Not stated | Oct 21, 2026 | Not stated |
| Laboratory Assistant (m/f/x) | UK-London | Not stated | Oct 21, 2026 | Not stated |
| Manager, Global Customer Operations | US-TN-Memphis | Not stated | Oct 16, 2026 | Mid |
| Senior Project Manager | US-Remote | Not stated | Oct 16, 2026 | Senior |
| Account Executive, Chicago | US-IL-Chicago | Not stated | Oct 16, 2026 | Mid |
| Supervisor Filling and Finishing (m/w/d) | Luckenwalde, Germany | Not stated | Oct 16, 2026 | Senior |
| R&D Scientist I | US-OH-Cincinnati | Not stated | Oct 16, 2026 | Entry |
| Scientist, Upstream Process Development | US-TN-Memphis | Not stated | Oct 16, 2026 | Senior |
| Senior Manager, Sourcing and Procurement | US-OH-Cincinnati | Not stated | Oct 16, 2026 | Senior |
| Project Manager | US-Remote | Not stated | Oct 16, 2026 | Mid |
| Assembler | US-OH-Cincinnati | Not stated | Oct 16, 2026 | Entry |
| Senior Manufacturing Engineer (1st Shift - Eastside) | US-OH-Cincinnati | Not stated | Oct 16, 2026 | Senior |
| Manager, R&D | US-MA-North Billerica | Not stated | Oct 16, 2026 | Senior |
| Assembler | US-OH-Cincinnati | Not stated | Oct 16, 2026 | Entry |
| Inside Sales Representative | US-Remote | Not stated | Oct 16, 2026 | Mid |
| Manager, Clinical Operations | US-OH-Cincinnati | Not stated | Oct 16, 2026 | Mid |
| Regional Point of Care Specialist - South Central | US-LA | Not stated | Oct 16, 2026 | Mid |
| Medical Device Cybersecurity Engineer | US-Remote | Not stated | Oct 16, 2026 | Mid |
| Network Administrator, Security Operations Support | US-OH-Cincinnati | Not stated | Oct 16, 2026 | Entry |
| Shipping Clerk I | US-OH-Cincinnati | Not stated | Oct 16, 2026 | Entry |
| Account Executive- Denver | US-CO | US-KS-Wichita | Not stated | Oct 16, 2026 | Mid |
| Technicien en comptabilité et administration | CA-QC-Quebec | Not stated | Oct 16, 2026 | Mid |
Connect
See your connections at Meridian Bioscience on LinkedIn (search by name, results not checked)